the Company had 37,561,205 shares of common stock issued and outstanding, of which 21,772,737 were held by non-affiliates. (think about these low numbers!,this could take off like BIPH did! Been reading the most recent 10K, thought I'd share some of my favorite quotes:
1. "The company believes that it will report a net profit for 2005."
2. Regarding LifeStem's stem cell banking service: "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients."
3. Officers and Directors:
James DeOlden, Esq. -- CEO: B.A. from UVA, J.D. from Whittier Law School, he has a securities law practice.
Edward Deese -- President, COO: B.S. in Economics from University of California, Irvine.
John Gordon, Ph.D. -- CTO: B.Sc. Honors in Cell Biology, Ph.D. from University of Glasgow.
4. Scientific Advisory Board:
Kary B. Mullis: Recieved the 1993 Nobel Prize in chemistry for his invention of the polymerase chain reaction (PCR). Ph.D. from Berkeley, B.S. from Georgia Institute of Technology.
Basically, the company looks like it's going to be profitable soon and the directors and advisors appear to be very intelligent people who are leaders in their respective fields.
CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board, that intend to contribute innovation in areas of biological discovery.
Contact: Paul Knopick (949) 707-5365 pknopick*eandecommunications.com
CalbaTech now looks to build a portfolio by buying companies that develop new technologies to sell or license; it also targets universities that are planning to license technology developed in academic labs. The firm is interested in products that will generate sales or licensing revenue within two years and need less than $1 million. Among its acquisitions are MolecularWare and iStem Technologies
MoleculareWare helps scientists have the wherewithal to keep their As, Cs, Gs, and Ts straight. The firm, a subsidiary of CalbaTech, offers bioinformatics software and other products to integrate the volumes of data produced from high throughput screening, combinatorial synthesis, and other methods of genomics research. Its DigitalGENOME suite consists of three software programs. DesignerDG can configure microplates and track the liquids used in the microplate wells. AnalyzerDG analyzes images and manages data from microarrays; the software can be used as part of DigitalGENOME or on its own. IntegratorDG can integrate data stored in a variety of database platforms, including platforms from Oracle and Microsoft.
CalbaTech, Inc., (CLBE) said its wholly owned subsidiary, K-D Medical, Inc., Columbia, Maryland, is acquiring a new facility that has two validated, Class 100 Clean Rooms for additional manufacture of products.
K-D Medical is a primary vendor to the National Institutes of Health (NIH) and currently sells products to every major pharmaceutical company in the U.S. K-D Medical's founder, John Powers, said the new Clean Rooms, plus a complete quality control laboratory, will allow the company to manufacture a higher quality product as well as expand the current custom product offering, better serving the needs of both existing and new customers.
"This is a very good position for us, as we increase sales to the National Institutes of Health, major universities and pharmaceutical companies," Powers said.
"These new facilities allow K-D Medical to open new manufacturing and Clean Room leasing opportunities with pharmaceutical and other companies, opportunities that did not exist prior to this," said James DeOlden, chairman and CEO, CalbaTech. "We are very bullish on our subsidiary's future."
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.
NewsRx.com) -- CalbaTech, Inc., (CLBE) has retained the services of Agora Investor Relations Corp. (Agora).
The objective of this agreement is two-fold. First, to create effective communication between CalbaTech, its shareholders and the investment community through Agora's Internet based investor relations system. Effective immediately, a customized and monitored CalbaTech IR HUB will allow both CalbaTech and Agora to communicate with all investors simultaneously, anytime and in real-time, while providing shareholders with equal access and complete transparency to all investor relations communications.
The IR HUB will also provide one-click access to the CalbaTech broker fact sheet, company profile, five most recent press releases, e-mail list registration, latest stock quote and chart information and an executive audio address updated quarterly. In addition, the IR HUB provides investors with a monitored discussion forum for the purposes of constructive and high-quality discussion about the company that is free of spam, bashing, hyping and profanity.
Second, Agora will be fully responsible for creating, implementing and executing an investor relations strategy, the consolidation of which will save management a considerable amount of time, effort and expense, allowing them to focus on core business operations, while significantly improving shareholder communications.
CalbaTech CEO James DeOlden stated, "We believe that the time is right to begin an investor awareness program. CalbaTech has been executing its business plan, and given the company's recent developments and the excitement being generated in the life sciences Industry, we believe the time has now come to significantly increase our communications with shareholders and the investment community."
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
